Institutional members access full text with Ovid®

Share this article on:

Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia

Golubchik, Pavela,d; Sever, Jonathana,d; Weizman, Abrahamb,c,d

International Clinical Psychopharmacology: July 2014 - Volume 29 - Issue 4 - p 212–215
doi: 10.1097/YIC.0000000000000029
Original Articles

The aim of this study was to assess the response of social phobia (SP) symptoms to methylphenidate (MPH) treatment in children with attention deficit hyperactivity disorder (ADHD). Twenty-one ADHD patients with SP, aged between 8 and 18 years, received 12 weeks of MPH treatment. The severity of SP symptoms were assessed by the Liebowitz Social Anxiety Scale for Children and Adolescents (LSAS-CA), and the severity of ADHD symptoms was assessed by the ADHD Rating Scale at baseline and at endpoint. MPH treatment was associated with a significant decrease in the ADHD Rating Scale scores (P<0.0001) and in the total LSAS-CA scores (P=0.013), as well as the school-related items of LSAS-CA (P=0.011). A significant correlation was found between the reductions in ADHD score and total LSAS-CA score (P=0.038), especially in school-related SP. The improvement in ADHD symptoms because of MPH treatment correlates with a parallel improvement in SP. MPH treatment appears to be safe and effective in ADHD/SP children.

aChild and Adolescent Outpatient Clinic

bResearch Unit, Geha Mental Health Center

cFelsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva

dSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

Correspondence to Pavel Golubchik, MD, Child and Adolescent Outpatient Clinic, Geha Mental Health Center, 1 Helsinki St, PO Box 102, Petah Tikva 4910002, Israel Tel: +972 3 9258270; fax: +972 3 9523598; e-mail:

Received November 4, 2013

Accepted December 19, 2013

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins